Skip to NavigationSkip to content

juno therapeutics

Juno CEO and Co-founder steps down in wake of Celgene acquisition

Hans Bishop, CEO and Co-founder of Juno Therapeutics who helped set up the company in 2013 and has since grown it more than 500 employees, is to step down from his role now that his company has been acquired by Celgene in a $9 billion deal earlier this year, it has emerged.

Read Pharmafocus January/February 2018 edition online now!

With the holiday period a distant memory by now, Pharmafocus is back with its January/febraury edition. It’s hard to imagine a more explosive start to the year, as the dust that had settled on a year characterised by stagnation in the mergers & acquisitions department is swiftly blown away with two major deals in one day: Sanofi shells out $11.6 billion for Bioverativ, and Celgene splashes $9 billion to acquire the rest of Juno Therapeutics.

Celgene confirms rumours, with $9bn deal for Juno

It seems like 2018 may well be the year for M&A that everyone had expected, as two major deals on the same day announced that acquisitions were back with a bang.

First, Sanofi managed to achieve a long-held goal of making a sizeable addition to its business and now Celgene has made the plunge to acquire Juno Therapeutics in a $9 billion deal.

Top Ten most popular articles on Pharmafile.com this week

It's Friday, so it's time to bring you another run-down of the top ten most popular articles with Pharmafile.com's readers this week.

Despite a drought of mergers and acquisitions throughout 2017, rumours are already circulating on what deals may occur this year, and among them, Celgene is expected to attempt to acquire Juno Therapeutics and the valuable CAR T therapy it is developing for $7 billion.

Ex-Genentech exec named as new Juno Therapeutics CIO

Published on: 08/01/18

Biopharmaceutical firm and cellular immunotherapy specialist Juno Therapeutics has named Cindy Elkins as its new Chief Information Officer, where she will report to President and CEO Hans Bishop.

Juno Therapeutics bring in new executive vice president

Published on: 27/01/17

Juno Therapeutics has hired Corsee D. Sanders as its executive vice president and head of development operations. She will step into the role immediately, joining Juno after nearly five years working at Roche as global head of Roche pharmaceuticals clinical operations and external collaboration.

Prior to working in this role, she was held several roles at Genentech for 17 years. In this role, Sanders oversaw the development and submission of Rituxan, Herceptin and Avastin.

Patient deaths lead Juno Therapeutics to halt trial for second time

Juno Therapeutics has been forced to halt a trial investigating the efficacy of its lead experimental CAR-T cancer treatment JCAR015 for acute lymphoblastic leukaemia (ALL) after two participants died following severe swelling of the brain. This disaster follows the deaths of three patients from cerebral edema in July earlier this year.

Weekly Movers: CytRx, Coherus BioSciences, Juno Therapeutics…

Published on 15/07/16 at 02:52pm

Shares in CytRx (Nasdaq: CYTR) lost nearly three-fourth in value after the company reported disappointing late-stage results for its lead drug candidate, aldoxorubicin, for cancer.

Busy week at Juno Therapeutics ends with takeover of RedoxTherapies

Juno Therapeutics (NASDAQ: JUNO) has announced the acquisition of RedoxTherapies, adding its lead cancer drug candidate, vipadenant, to its portfolio.

US FDA lifts hold on Juno’s CAR-T therapy trials; shares jump

Shares in Juno Therapeutics (Nasdaq: JUNO) jumped to close up almost 30% after the company said the US Food and Drug Administration (FDA) has lifted the hold on mid-stage trials for chimeric antigen receptor T cell (CAR-T) therapy to potentially treat blood cancer.

Last week the regulators placed on hold the trials for refractory B cell acute lymphoblastic leukaemia following the deaths of two patients from cerebral oedema.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches